

1 **Title: Investigating SARS-CoV-2 surface and air contamination in an acute healthcare**
2 **setting during the peak of the COVID-19 pandemic in London**

3

4 **Running Title: SARS-CoV-2 air and surface contamination**

5

6 **Authors:** Jie Zhou,^{1*} Jonathan A. Otter,^{2,3*} James R. Price,^{2,3} Cristina Cimpeanu,³ Danel
7 Meno Garcia,³ James Kinross,^{3,4} Piers R Boshier,^{3,4} Sam Mason,^{3,4} Frances Bolt,^{2,3} Alison H.
8 Holmes,^{2,3} Wendy S. Barclay¹

9 * Joint first authors

10 **Affiliations:**

- 11 1. Department of Infectious Disease, Imperial College London, London, UK, W2 1PG.
12 2. National Institute for Healthcare Research Health Protection Research Unit (NIHR
13 HPRU) in HCAI and AMR, Imperial College London & Public Health England,
14 Hammersmith Hospital, Du Cane Road, W12 0HS.
15 3. Imperial College Healthcare NHS Trust, St. Mary's Hospital, Praed Street, London,
16 W2 1NY, UK.
17 4. Department of Surgery and Cancer, Imperial College London, London, UK, W2 1NY.

18

19 **Corresponding author:** Dr Jonathan Otter, Imperial College London, NIHR Health
20 Protection Research Unit, Hammersmith Hospital, Du Cane Road, W12 0HS. Tel: 020 331
21 33271, Email: j.otter@imperial.ac.uk.

22

23 **Key words:** SARS-CoV-2, COVID-19, transmission, air contamination, surface
24 contamination

25 **Key points:** The role of surface and air contamination in SARS-CoV-2 transmission was
26 evaluated in a London hospital. Whilst SARS-CoV-2-RNA was detected no viable virus was
27 recovered. This underlines the potential risk of environmental contamination and the need
28 for effective IPC practices.

29 ***Author contributions***

30 All authors met the ICMJE criteria for authorship. JZ and JAO conceived the study, collected
31 and analysed data, and wrote the manuscript; JRP conceived the study, collected data, and
32 contributed to the manuscript; CP, DMG, PRB, SM collected data and contributed to the
33 manuscript; FB, AHH, and ASB conceived the study, analysed data, and contributed to the
34 manuscript. JAO is the study guarantor.

35

36 **ABSTRACT**

37

38 **Background:** Evaluation of SARS-CoV-2 surface and air contamination during the COVID-
39 19 pandemic in London.

40 **Methods:** We performed this prospective cross-sectional observational study in a multi-site
41 London hospital. Air and surface samples were collected from seven clinical areas, occupied
42 by patients with COVID-19, and a public area of the hospital. Three or four 1.0 m³ air
43 samples were collected in each area using an active air sampler. Surface samples were
44 collected by swabbing items in the immediate vicinity of each air sample. SARS-CoV-2 was
45 detected by RT-qPCR and viral culture; the limit of detection for culturing SARS-CoV-2 from
46 surfaces was determined.

47 **Results:** Viral RNA was detected on 114/218 (52.3%) of surfaces and 14/31 (38.7%) air
48 samples but no virus was cultured. The proportion of surface samples contaminated with
49 viral RNA varied by item sampled and by clinical area. Viral RNA was detected on surfaces
50 and in air in public areas of the hospital but was more likely to be found in areas immediately
51 occupied by COVID-19 patients than in other areas (67/105 (63.8%) vs. 29/64 (45.3%) (odds
52 ratio 0.5, 95% confidence interval 0.2-0.9, p=0.025, Chi squared test)). The high PCR Ct
53 value for all samples (>30) indicated that the virus would not be culturable.

54 **Conclusions:** Our findings of extensive viral RNA contamination of surfaces and air across
55 a range of acute healthcare settings in the absence of cultured virus underlines the potential

56 risk from environmental contamination in managing COVID-19, and the need for effective

57 use of PPE, physical distancing, and hand/surface hygiene.

58

59 **INTRODUCTION**

60

61 Since it was identified in Wuhan, China, in late 2019, the severe acute respiratory syndrome
62 coronavirus (SARS-CoV-2) has rapidly spread around the world, resulting in a coronavirus
63 disease 2019 (COVID-19) pandemic.[1] Experience from previous SARS and influenza
64 outbreaks and emerging evidence for SARS-CoV-2 suggests droplet and contact spread as
65 primary transmission routes.[1, 2] Additionally, there is evidence that airborne spread can
66 occur during aerosol generating procedures.[1, 2]

67

68 In-hospital transmission to patients and healthcare workers was a key feature of SARS-CoV-
69 1.[1, 3] Hospital-onset COVID-19 infection has been reported, probably due to inadequate
70 implementation of effective infection prevention and control measures.[4] The dynamics of
71 transmission in the health care environment are unclear and likely to be multifactorial.
72 Contaminated surfaces and air are recognised as a key part of the transmission dynamic of
73 SARS, MERS, influenza, and other organisms in hospitals.[1, 2, 5] Laboratory evidence
74 suggests that the SARS-CoV-2 virus can survive on dry surfaces and in aerosols for days to
75 weeks, particularly on non-porous surfaces.[6, 7] Furthermore, SARS-CoV-2 RNA has been
76 detected on surfaces and in the air in hospitals that are caring for patients with COVID-19.[8-
77 16]

78

79 However, our understanding of the role of surface and air contamination in the transmission
80 of SARS-CoV-2 is limited. Most studies to date have relied on PCR to detect SARS-CoV-2
81 on surfaces and in air, and have not attempted to culture live virus thereby limiting the ability
82 to interpret the relevance of detection by PCR; most studies published so far have focussed
83 upon one geographical region (Asia), and included a limited selection of clinical and non-
84 clinical areas were included with no evidence from operating theatre environments.[8, 9, 11,
85 12, 14, 15] In mid-April 2020, the UK was experiencing the first wave of the COVID-19
86 pandemic. During this period, there was evidence for hospital acquired infections with

87 COVID-19.[17] Therefore, to inform and optimise infection prevention and control
88 interventions, we evaluated surface and air contamination across a range of clinically-
89 relevant locations (including operating theatres) and public areas during the peak of the
90 COVID-19 pandemic in London, using both RT-PCR and viral culture to detect SARS-CoV-
91 2. We also performed supporting laboratory experiments to provide evidence on the viability
92 of SARS-CoV-2 on surfaces, with associated limits of detection to qualify our findings.

93

94 **METHODS**

95

96 ***Setting***

97 Sample collection for this prospective cross-sectional study was performed between April 2nd
98 and 20th 2020 on selected wards at a large North West London teaching hospital group
99 comprising five hospitals across four sites with 1,200 acute beds, which prior to the
100 pandemic undertook 1.2 million episodes of patient contact per year. Most sampling was
101 conducted on one hospital site during the peak of the COVID-19 pandemic (Supplemental
102 Figure 1) when most patients were managed in cohort wards.

103

104 ***Clinical areas selected for air and surface sampling***

105 Seven clinical areas and a public area of the hospital were selected to represent a range of
106 clinical environments within our hospital group. These included:

- 107 • Adult emergency department, which included sections dedicated for suspected and
108 confirmed COVID-19 patients (with 19 cubicles and a 6-bedded resuscitation bay)
109 and for patients not suspected to have COVID-19 (with a two cubicle-bay, and two
110 four-cubicle bays).
- 111 • A 16-bedded COVID-19 cohorting adult acute admissions unit with four four-bedded
112 bay.

- 113 • A 32-bedded COVID-19 cohorting adult intensive care unit with four four-bedded
114 bays and 16 single rooms.
- 115 • Theatres during tracheostomy procedures.
- 116 • Two adult COVID-19 cohort wards: one 20-bed ward with four four-bedded bays and
117 four single rooms, and one 19-bed ward with a nine-bedded bay, an 8 bedded-bay
118 and two single rooms.
- 119 • An adult ward area including a 6-bedded bay converted into a negative pressure
120 area for management of continuous positive airway pressure (CPAP) on patients with
121 COVID-19.
- 122 • The entrance and public area of the main hospital building.

123

124 All inpatient wards were fully occupied by patients with COVID-19 at the time of sampling,
125 apart from the Emergency Department. In the part of the Emergency Department dedicated
126 for patients with confirmed or suspected COVID-19, two of the cubicles were occupied and
127 one patient was in the ambulatory wait area at the time of sampling. These areas were
128 disinfected daily using a combined chlorine-based detergent/disinfectant (Actichlor Plus,
129 Ecolab), with an additional twice daily disinfection of high touch surfaces using the same
130 detergent/disinfectant.

131

132 In each of these clinical areas, four air samples were collected (five air samples were
133 collected in the Emergency Department, and three in public areas of the hospital). Surfaces
134 in the immediate vicinity of each air sample that were considered to be touched frequently by
135 staff or patients were sampled. These included bed rails, clinical monitoring devices (blood
136 pressure monitors), ward telephones, computer keyboards, clinical equipment (syringe
137 pumps, urinary catheters), hand-cleaning facilities (hand washing basins, alcohol gel
138 dispensers). In each clinical area, sampling was performed in both patient (i.e. bays and
139 single rooms) and non-patient care areas (i.e. nursing stations and staff rooms).

140 Environmental sampling was conducted during three tracheostomy procedures. During the
141 first procedure, air sampling was performed before and during the procedure; for the other
142 procedures, air sampling was performed during the procedure only.

143

144 ***Sampling methods***

145 Air sampling was performed using a Coriolis μ air sampler (referred to as Coriolis hereafter)
146 (Bertin Technologies), which collects air at 100–300 litres per minute (LPM). After 10 min
147 sampling at 100 LPM, a total of 1.0 m³ air was sampled into a conical vial containing 5 mL
148 Dulbeccos's minimal essential medium (DMEM). Surface samples were collected by
149 swabbing approximately 25 cm² areas of each item using flocked swabs (Copan, US)
150 moistened in DMEM. Temperature, humidity and time of day were recorded at the time of
151 sampling. In all clinical settings, samples were taken in order from the lowest to highest
152 perceived risk of SARS-CoV-2 contamination.

153

154 ***Detection and quantification of SARS-CoV-2 viral RNA genome and viral culture***

155 Viral RNA detection and absolute quantification was performed using quantitative real-time
156 reverse transcription polymerase chain reaction (RT-qPCR). Samples were extracted from
157 140 μ L of the DMEM medium using the QIAamp viral RNA mini Kit according to the
158 manufacturer's instructions (Qiagen, Germany). Negative controls (water) were extracted
159 and included in the PCR assays. SARS-CoV-2 viral RNA was detected using AgPath-ID
160 One-Step RT-PCR Reagents (Life Technologies) with specific primers and probes targeting
161 the envelop (E) gene.[18] The number of SARS-CoV-2 virus E gene copies per m³ air and
162 copies per swab were calculated. All samples were run in duplicate.

163

164 Viral culture: Vero E6 (African Green monkey kidney) and Caco2 (human colon carcinoma)
165 cells were used to culture virus from air and environmental samples. The cells were cultured
166 in DMEM supplemented with heat inactivated fetal bovine serum (10%) and
167 Penicillin/Streptomycin (10, 000 IU/mL & 10, 000 μ g/mL). For propagation, 200 μ L of

168 samples were added to 24 well plates. After 5-7 days, cell supernatants were collected, and
169 RT-qPCR to detect SARS-CoV-2 performed as described above. Samples with at least one
170 log increase in copy numbers for the E gene (reduced Ct values relative to the original
171 samples) after propagation in cells were considered positive by viral culture.

172

173 We defined samples where both of the PCRs performed from an air or surface sample
174 detected SARS-CoV-2 RNA as positive, and samples where one of the two PCRs performed
175 from an air or surface sample detected SARS-CoV-2 RNA as suspected.

176

177 We performed a laboratory experiment to determine the limit of detection for culturing SARS-
178 CoV-2 dried on surfaces. A dilution series from solution containing 8.25×10^6 PFU/mL SARS-
179 CoV-2 (titred by plaque assay in Vero cells) from 10^{-3} to 10^{-6} (covering Ct values from 26 to
180 36) was produced in DMEM and 50 μ L inoculated in triplicate onto the surface of plastic
181 (standard keyboard key) or stainless steel (2 x 1 x 0.2 cm) pieces. The inoculated surfaces
182 were dried in a safety cabinet for 2 hours after which they were visibly dry. They were then
183 sampled using flocked swabs. Swabs were deposited into 1.5 mL of DMEM for 1 hour. RT-
184 qPCR was used to determine viability following 7 days of culture as follows. 140 μ L was
185 used for RNA extraction and qPCR immediately (0 days post inoculation, dpi) and after
186 incubation for 7 days in a 24-well plate with VeroE6 cells (7 dpi). Samples with an increase
187 in copy numbers for the E gene (reduced Ct values relative to the original samples) after
188 propagation in Vero E6 cells were considered positive by viral culture.

189

190 ***Statistical analysis***

191 A Chi square test was used to compare the proportion of environmental samples (surfaces
192 or air) that were positive or suspected for SARS-CoV-2 RNA in areas immediately occupied
193 by patients with COVID-19 with other areas. The mean concentration of air and surface
194 contamination in each of the areas was log transformed and then compared by one-way
195 ANOVA followed by Tukey's multiple comparisons test.

196

197 ***Ethics approval***

198 The work was registered locally as an NHS service evaluation (#434).

199

200 **RESULTS**

201

202 114/218 (52.3%) of surface samples were suspected (91/218 (41.7%)) or positive (23/218
203 (10.6%)) for SARS-CoV-2 RNA but no virus was cultured (Table 1). The proportion of
204 surface samples contaminated varied by item, with suspected or positive RNA samples
205 identified on >80% of computer keyboards/mice, alcohol gel dispensers, and chairs, and >50%
206 of toilet seats, sink taps, and patient bedrails (Figure 1). A similar pattern was observed in air
207 samples; no virus was cultured, but 14/31 (38.7%) of samples were suspected (12/31
208 (38.7%)) or positive 92/31 (6.4%) for SARS-CoV-2 RNA (Table 1).

209

210 SARS-CoV-2 RNA was detected in air samples from all eight areas tested with levels
211 ranging from 10^1 to 10^3 genome copies / m^3 (Table 1); there was no significant difference in
212 mean viral RNA concentration across the eight areas tested ($p=0.826$). Similarly, SARS-
213 CoV-2 RNA was detected in surface samples from all eight areas tested, with levels ranging
214 from 10^1 to 10^4 copies per swab (Figure 2). There was a significant difference in the mean
215 SARS-CoV-2 surface viral load across the eight areas tested ($p=0.004$), with both Cohort
216 Ward A and the Temporary CPAP ward showing higher levels of viral RNA; Cohort Ward A
217 (mean = $1.76 \log_{10}$ copies/swab) > Adult ICU (mean = $0.0018 \log_{10}$ copies/swab) ($p = 0.015$),
218 and the Temporary CPAP Ward (mean = $1.69 \log_{10}$ copies/swab) > Adult ICU ($p = 0.016$).

219

220 Several clinical areas where AGPs are commonly performed were sampled. A suspected
221 positive air sample was collected in the resuscitation bay in the emergency department,
222 where aerosol generating procedures are commonly performed (although had not been
223 performed for more than two hours prior to sample collection). In a ward temporarily

224 converted for CPAP, SARS-CoV-2 RNA was detected from air within the negative pressure
225 CPAP bay, and outside the bay. No patient was undergoing CPAP at the time of sampling,
226 but one patient was undergoing high-flow nasal cannula (HFNC) oxygen therapy. In the
227 adult ICU, 3/4 air samples were suspected or positive. In operating theatres, 1/3 air samples
228 collecting during three tracheostomy procedures was positive.

229

230 SARS-CoV-2 RNA was detected in surface and air samples in parts of the hospital hosting
231 staff but not being used for direct patient care, including the staff room in the ICU, the
232 nursing station outside of the CPAP unit, and in the hospital main entrance and public toilets.
233 However, positive or suspected air and surface samples were significantly more likely to be
234 found in areas immediately occupied by COVID-19 patients than in other areas (67/105
235 (63.8%) in areas immediately occupied by COVID-19 patients vs. 29/64 (45.3%) in other
236 areas (odds ratio 0.5, 95% confidence interval 0.2-0.9, $p=0.025$).

237

238 Since viable virus was not cultured from any of the air or surface samples, we performed
239 laboratory experiments to determine the limit of detection of SARS-CoV-2 dried onto
240 surfaces. Viable SARS-CoV-2 virus could be cultured from experimentally contaminated
241 dried surfaces with a Ct value <30 ; this was consistent for plastic and metal test surfaces
242 (Table 2). In our study, all surface and air samples from the hospital environment had a Ct
243 value >30 .

244

245 **DISCUSSION**

246

247 SARS-CoV-2 RNA was detected frequently from surface and air samples but we did not
248 identify viable virus in any surface or air sample. Furthermore, our simulated laboratory
249 studies showed that the RNA levels detected on environmental surfaces in the hospital were
250 lower than the minimum that can be cultured from surfaces two hours after virus is
251 deposited. SARS-CoV-2 RNA was identified across the eight areas that we tested, including

252 areas of the hospital not used to care for patients with COVID-19 (e.g. public areas of the
253 hospital). However surface and air contamination was significantly more frequent in areas
254 immediately occupied by COVID-19 patients than in other areas.

255

256 A direct comparison between our findings and other studies that have evaluated
257 contamination of surfaces and air with SARS-CoV-2 is not possible due to differences in:
258 environmental sampling strategy (including which clinical areas were included, which
259 surfaces were sampled, and where air samples were collected from); experimental methods
260 (including the method for sampling surfaces and the sampler used for air); the phase of the
261 pandemic during which sampling was performed; the physical layout of buildings and clinical
262 spaces (including the efficiency of air handling systems); individual patient characteristics
263 that have been shown to influence shedding of SARS-CoV-2 and other hospital pathogens
264 including the stage and severity of disease and site of infection;[4, 19] and the patient and
265 staff testing, and cleaning and disinfection protocols. Nonetheless, our finding of widespread
266 detection of viral RNA on surfaces (114/218, 52.3%) and to a lesser extent air (14/31,
267 38.7%) is broadly consistent with the findings of most others although the proportion of
268 surface and air samples positive for viral RNA is higher in our study.[8-13] For example, Ye
269 et al. performed PCR detection of surface contamination in a range of clinical settings in a
270 hospital caring for patients with COVID-19 in Wuhan, China.[9] Overall, 14% of 626 surface
271 samples were positive for viral RNA, with a higher proportion of surface samples positive in
272 the ICU (32% of 69 samples). However, other studies have identified very little or no
273 contamination of surfaces or air.[8, 10] Other studies have observed higher frequencies of
274 contamination in patient-care vs. non-patient-care areas,[8, 9, 11] and variation in the
275 frequency of contamination across different clinical areas, which is in line with our
276 findings.[9, 11] One surprising finding in our study was that the level of contamination on
277 surfaces in the ICU was lower than in a cohort general ward or in the temporary CPAP ward,
278 in contrast to other findings.[9] This may be because patients sampled in the ICU were on
279 closed circuit ventilation systems through cuffed endotracheal tubes, which may have a

280 lower risk of producing surface and air contamination than other ventilation systems such as
281 CPAP.

282

283 We did not identify viable virus on any surface or air sample. Few studies have attempted to
284 culture SAR-CoV-2 from healthcare environments, and no viable virus was detected.[10, 14]
285 Our laboratory study of the viability of virus dried on surfaces helps to qualify our findings
286 and the findings of others, suggesting that Ct values of >30 are unlikely to be culturable.
287 Bearing in mind that the viral RNA detected in the hospital setting might have been
288 deposited more than two hours previously, we cannot differentiate whether our inability to
289 culture virus from the samples is explained by the low RNA levels or the length of time since
290 deposition or both. It is also possible that virus was infectious but not culturable in the
291 laboratory.

292

293 Surface contamination was detected on a range of items. Computer keyboards, chairs, and
294 alcohol dispensers had the highest proportion of positive/suspected SAS-CoV-2 samples.
295 Other studies have also identified computer keyboards and/or mice as a risk for
296 contamination with SARS-CoV-2 RNA.[8, 9, 11] Many of the computers that we sampled
297 were in shared staff clinical areas (such as nursing stations), so this argues for frequent
298 disinfection of these items. The contamination of alcohol gel dispensers is unsurprising since
299 staff hands activate these before hand hygiene is performed. However, alcohol gel
300 dispensers should be included in routine cleaning and disinfection protocols or designed
301 such that they can be activated without touching.

302

303 We sampled several areas where aerosol generating procedures are commonly performed
304 including the resuscitation bay in the emergency department, ICU, temporary CPAP ward,
305 and operating theatres during tracheostomies. Positive or suspected air samples were
306 identified in all of these clinical areas at a level of 10^1 to 10^3 copies / m^3 . There was no
307 difference in the viral load of the air across the eight areas sampled, which provides some

308 evidence that AGPs do not produce persistently high levels of air contamination. However,
309 we did not sample the air over time, and our air sampling method did not differentiate
310 particle size so we are unable to distinguish droplets from aerosols (< 5 μM). One recent
311 study evaluated contamination of the air with SARS-CoV-2 in a permanent hospital and in a
312 field hospital in Wuhan, China.[13] Viral culture was not performed, but viral RNA was
313 identified a low levels (in the 10^1 - 10^2 range copies per m^3) in patient care areas, and was not
314 detected or detected in very low levels in public areas. Positive samples were identified in a
315 range of particle sizes, including those <5 μM , which would typically be considered as
316 aerosols.[2] It seems likely, therefore, that the positive and suspected air samples identified
317 in our study included a range of particle sizes spanning 5 μM , particularly in areas where
318 aerosol generating procedures are common.

319

320 Whilst we performed sampling in a temporary CPAP ward, no patient was undergoing CPAP
321 at the time of sampling. However, one patient was undergoing HFNC during the time of
322 sample, and air contamination was identified <1 m from this patient. A recent summary of
323 evidence concludes that HFNC is a lower risk procedure in terms of aerosol generation than
324 CPAP, which should be a topic for future studies.[20]

325

326 We identified contamination of surfaces and air during three tracheostomy procedures.
327 Several studies and commentaries have evaluated the potential for various surgical
328 procedures to produce aerosols for patients with COVID-19.[21-23] One study evaluated the
329 spread of droplets during tracheostomies, although did not include sampling for SARS-CoV-
330 2.[21] Whilst our methods did not include measurement of particle size, our findings highlight
331 a potential theoretical risk of transmission of COVID-19 during these procedures. However,
332 a larger sample size is required to understand this risk

333

334 Our study has important strengths and limitations. Strengths include our sampling strategy
335 encompassing contemporaneous surface and air samples from a range of clinical services

336 including both patient care and non-patient care areas, specifically, we included operating
337 theatres and areas dedicated to known and potential AGPs; each sample was tested using
338 PCR and also viral culture, and we performed laboratory viral culture experiments to quality
339 our findings; the sampling was conducted during the peak of the pandemic (and so likely
340 represents a worst-case scenario) in a European hospital group. Limitations include not
341 collecting patient samples to better understand how our findings links to patient samples,
342 particularly during tracheostomies and AGPs; no asymptomatic patient or staff testing
343 ongoing at the time of sampling, which means patients and staff without known COVID-19
344 could have been shedding SARS-CoV-2 and this would explain the detection of SARS-CoV-
345 2 RNA in non-patient care areas; challenges in interpreting the significance of samples with
346 low viral loads, ; a lack of resolution of particle sizes for contamination of the air; and no
347 longitudinal sampling was performed so these findings represent a “snapshot”.

348

349 Our findings may have implications for future policy and guidelines. Most international
350 guidelines recommend enhanced surfaces disinfection during the management of COVID-
351 19. For example, Public Health England recommends enhanced disinfection using a
352 chlorine-based disinfectant (or a disinfectant with effectiveness against coronaviruses).[24]
353 Our finding of widespread RNA contamination of clinical areas used to care for patients with
354 COVID-19 supports the need for enhanced disinfection. Physical distancing is
355 recommended by most governments and personal protective equipment (PPE) is
356 recommended during contact with patients with COVID-19 plus higher levels of PPE for
357 performing aerosol generating procedures. Whilst we did not measure particle sizes during
358 our air sampling, our findings highlight a potential role for contaminated air in the spread of
359 COVID-19. Our finding of air contamination outside of clinical areas should be considered
360 when making respiratory PPE recommendations in healthcare settings.[25]

361

362 Whilst SAR-CoV-2 RNA was detected within healthcare environments, further research
363 linking patient, staff and environmental samples is required to better understand

364 transmission routes. Longitudinal environmental and clinical sampling across healthcare
365 settings is required to understand risk factors associated with viral shedding and
366 transmission. Our findings can be used to parameterise mathematical models of COVID-19
367 transmission. Finally, our methods can be used to assess the potential risk associated with
368 various procedures including some surgical and other procedures such as CPAP and
369 nebulisation of medications. Findings from these studies may prompt changes to PPE
370 recommendations for specific procedures, and the implementation of various innovative
371 tools and approaches to reduce viral shedding (such as “helmet CPAP”).[26-28]

372

373 Whilst SARS-CoV-2 RNA was detected in clinical and non-clinical areas, no viable virus was
374 recovered. These results are in line with other studies which have identified viral RNA but no
375 viable SARS-CoV-2 within healthcare environments. Our findings of extensive viral RNA
376 contamination of surfaces and air across a range of acute healthcare settings in the absence
377 of cultured virus underlines the potential risk from surface and air contamination in managing
378 COVID-19, and the need for effective use of PPE, physical distancing, and hand/surface
379 hygiene.

380

381 **ACKNOWLEDGEMENTS**

382 We wish to acknowledge the staff teams and patients who supported this sampling during
383 the peak of the challenges posed by this pandemic.

384

385 **FUNDING**

386 The authors would like to acknowledge the support of the NIHR Imperial Biomedical
387 Research Centre, the Health Research Health Protection Research Unit (NIHR HPRU) in
388 HCAI and AMR and the HPRU in Respiratory Infections at Imperial College.

389

390 The views expressed in this publication are those of the author(s) and not necessarily those
391 of the NHS, the National Institute for Health Research, the Department of Health and Social

392 Care or Public Health England. Professor Alison Holmes is a National Institute for Health
393 Research (NIHR) Senior Investigator. International Severe Acute Respiratory and Emerging
394 Infection Consortium (ISARIC) provided funding for JZ and laboratory materials used for this
395 study.

396

397 REFERENCES

- 398 1. Wilder-Smith A, Chiew CJ, Lee VJ. Can we contain the COVID-19 outbreak with the
399 same measures as for SARS? *The Lancet Infectious diseases*, **2020**; 20: e102-e7.
- 400 2. Otter JA, Donskey C, Yezli S, Douthwaite S, Goldenberg SD, Weber DJ. Transmission
401 of SARS and MERS coronaviruses and influenza virus in healthcare settings: the
402 possible role of dry surface contamination. *The Journal of hospital infection*, **2016**;
403 92: 235-50.
- 404 3. Gowri G, Philip C, Yee Sin L, et al. SARS Transmission and Hospital Containment.
405 *Emerging Infectious Disease journal*, **2004**; 10: 395.
- 406 4. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility
407 of COVID-19. *Nature medicine*, **2020**; 26: 672-5.
- 408 5. Otter JA, Yezli S, Salkeld JA, French GL. Evidence that contaminated surfaces
409 contribute to the transmission of hospital pathogens and an overview of strategies
410 to address contaminated surfaces in hospital settings. *Am J Infect Control*, **2013**; 41:
411 S6-S11.
- 412 6. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of
413 SARS-CoV-2 as Compared with SARS-CoV-1. *The New England journal of medicine*,
414 **2020**; 382: 1564-7.
- 415 7. Chin AWH, Chu JTS, Perera MRA, et al. Stability of SARS-CoV-2 in different
416 environmental conditions. *The Lancet Microbe*, **2020**; 1: e10.
- 417 8. Wu S, Wang Y, Jin X, Tian J, Liu J, Mao Y. Environmental contamination by SARS-CoV-
418 2 in a designated hospital for coronavirus disease 2019. *Am J Infect Control*, **2020**:
- 419 9. Ye G, Lin H, Chen S, et al. Environmental contamination of SARS-CoV-2 in healthcare
420 premises. *The Journal of infection*, **2020**:
- 421 10. Wang J, Feng H, Zhang S, et al. SARS-CoV-2 RNA detection of hospital isolation wards
422 hygiene monitoring during the Coronavirus Disease 2019 outbreak in a Chinese
423 hospital. *International journal of infectious diseases : IJID : official publication of the*
424 *International Society for Infectious Diseases*, **2020**; 94: 103-6.
- 425 11. Guo ZD, Wang ZY, Zhang SF, et al. Aerosol and Surface Distribution of Severe Acute
426 Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020.
427 *Emerging infectious diseases*, **2020**; 26:
- 428 12. Ong SWX, Tan YK, Chia PY, et al. Air, Surface Environmental, and Personal Protective
429 Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2
430 (SARS-CoV-2) From a Symptomatic Patient. *Jama*, **2020**; 323: 1610-2.
- 431 13. Liu Y, Ning Z, Chen Y, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan
432 hospitals. *Nature*, **2020**:
- 433 14. Colaneri M, Seminari E, Novati S, et al. SARS-CoV-2 RNA contamination of inanimate
434 surfaces and virus viability in a health care emergency unit. *Clinical microbiology and*

- 435 infection : the official publication of the European Society of Clinical Microbiology
436 and Infectious Diseases, **2020**:
- 437 15. Chia PY, Coleman KK, Tan YK, et al. Detection of air and surface contamination by
438 SARS-CoV-2 in hospital rooms of infected patients. *Nature communications*, **2020**;
439 11: 2800.
- 440 16. Santarpia JL, Rivera DN, Herrera V, et al. Transmission Potential of SARS-CoV-2 in
441 Viral Shedding Observed at the University of Nebraska Medical Center. *medRxiv*,
442 **2020**: 2020.03.23.20039446.
- 443 17. Evans S, Agnew E, Vynnycky E, Robotham JV. The impact of testing and infection
444 prevention and control strategies on within-hospital transmission dynamics of
445 COVID-19 in English hospitals. *medRxiv*, **2020**: 2020.05.12.20095562.
- 446 18. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-
447 nCoV) by real-time RT-PCR. *Euro surveillance : bulletin European sur les maladies*
448 *transmissibles = European communicable disease bulletin*, **2020**; **25**:
- 449 19. Otter JA, Yezli S, French GL. The role played by contaminated surfaces in the
450 transmission of nosocomial pathogens. *Infection control and hospital epidemiology*,
451 **2011**; **32**: 687-99.
- 452 20. Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of
453 bio-aerosol dispersion. *The European respiratory journal*, **2020**:
- 454 21. Chow VLY, Chan JYW, Ho VWY, et al. Tracheostomy during COVID-19 pandemic-
455 Novel approach. *Head & neck*, **2020**:
- 456 22. Thamboo A, Lea J, Sommer DD, et al. Clinical evidence based review and
457 recommendations of aerosol generating medical procedures in otolaryngology -
458 head and neck surgery during the COVID-19 pandemic. *Journal of otolaryngology -*
459 *head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-*
460 *faciale*, **2020**; **49**: 28.
- 461 23. Lui RN, Wong SH, Sánchez-Luna SA, et al. Overview of guidance for endoscopy during
462 the coronavirus disease 2019 pandemic. *Journal of gastroenterology and hepatology*,
463 **2020**; **35**: 749-59.
- 464 24. PHE. COVID-19: infection prevention and control guidance
465 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attach](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/886668/COVID-19_Infection_prevention_and_control_guidance_complete.pdf)
466 [ment_data/file/886668/COVID-](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/886668/COVID-19_Infection_prevention_and_control_guidance_complete.pdf)
467 [19 Infection prevention and control guidance complete.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/886668/COVID-19_Infection_prevention_and_control_guidance_complete.pdf). **2020**:
- 468 25. Garcia Godoy LR, Jones AE, Anderson TN, et al. Facial protection for healthcare
469 workers during pandemics: a scoping review. *BMJ global health*, **2020**; **5**:
- 470 26. Radovanovic D, Rizzi M, Pini S, Saad M, Chiumello DA, Santus P. Helmet CPAP to
471 Treat Acute Hypoxemic Respiratory Failure in Patients with COVID-19: A
472 Management Strategy Proposal. *Journal of clinical medicine*, **2020**; **9**:
- 473 27. David AP, Jiam NT, Reither JM, Gurrola JG, 2nd, Aghi M, El-Sayed IH. Endoscopic Skull
474 Base and Transoral Surgery During the COVID-19 Pandemic: Minimizing Droplet
475 Spread with a Negative-Pressure Otolaryngology Viral Isolation Drape (NOVID). *Head*
476 *& neck*, **2020**:
- 477 28. Hirschmann MT, Hart A, Henckel J, Sadoghi P, Seil R, Mouton C. COVID-19
478 coronavirus: recommended personal protective equipment for the orthopaedic and
479 trauma surgeon. *Knee surgery, sports traumatology, arthroscopy : official journal of*
480 *the ESSKA*, **2020**: 1-9.
- 481

Table 1. PCR results from surface and air samples.

		SURFACE SAMPLES							AIR SAMPLES		
		Total	positive	%positive	suspect	%suspect	positive or suspect	% positive or suspect	Result	Concentration (copies/m ³)	Notes
Cohort ward A	Staff room	6	0	0.0	2	33.3	2	33.3	Negative		
	Nurse station	6	1	16.7	3	50.0	4	66.7	Negative		
	Toilet B (outside the patients' bay)	6	0	0.0	2	33.3	2	33.3	Negative		
	Cohort bay B	6	3	50.0	2	33.3	5	83.3	Positive	7048	
Cohort ward B	Staff room	4	0	0.0	0	0.0	0	0.0	Negative		
	Patients' toilet (in the ward)	7	0	0.0	1	14.3	1	14.3	Suspect	464	
	Male bay	12	1	8.3	4	33.3	5	41.7	Suspect	1335	
	Male bay (side room)	8	2	25.0	5	62.5	7	87.5	Suspect	163	
Adult acute admission unit	Ward managers office	5	1	20.0	2	40.0	3	60.0	Negative		
	Nurse station	7	0	0.0	5	71.4	5	71.4	Positive	404	
	Patient bay 2	8	0	0.0	2	25.0	2	25.0	Negative		
	Patient bay 1	10	0	0.0	8	80.0	8	80.0	Negative		
Adult emergency department	'Green' majors	10	1	10.0	5	50.0	6	60.0	Negative		
	Nurse station	4	2	50.0	0	0.0	2	50.0	Negative		
	Ambulatory waiting	3	2	66.7	1	33.3	3	100.0	Negative		
	Patient assessment cubicles	3	0	0.0	1	33.3	1	33.3			
	Male toilet (next to the nurse station)	2	0	0.0	1	50.0	1	50.0			
	Resus bay (last patient > 2 hours)	10	0	0.0	4	40.0	4	40.0	Suspect	35	
Hospital public areas	QEQM main entrance	7	1	14.3	4	57.1	5	71.4	Suspect	1574	
	Male toilet at QEQM main entrance	7	1	14.3	3	42.9	4	57.1	Suspect	1545	
	Lift area QEQM ground floor	10	0	0.0	4	40.0	4	40.0	Negative		
Temporary CPAP ward	Nurse station	5	1	20.0	2	40.0	3	60.0	Suspect	1922	
	CPAP unit	19	2	10.5	12	63.2	14	73.7	Suspect	31	< 1m from 2 patients
									Negative		> 2 m from patients
	PPE doffing area	5	0	0.0	2	40.0	2	40.0	Negative		
Adult ICU	Staff room	10	0	0.0	6	60.0	6	60.0	Suspect	249	
	Nurse station inside ICU	6	1	16.7	0	0.0	1	16.7	Negative		
	Bay area	11	0	0.0	5	45.5	5	45.5	Suspect	164	
	Side room bay area	8	2	25.0	4	50.0	6	75.0	Suspect	307	
Theatres	Theatres	13	2	15.4	1	7.7	3	23.1	Negative		Before tracheostomy
									Negative		During tracheostomy
									Suspect	1163	During tracheostomy
									Negative		During tracheostomy
	Total	218	23	10.6	91	41.7	114	52.3	2/31 (6.4%) positive; 12/31 (38.7%) suspect		

Table 2: Viability of SARS-CoV-2 dried onto steel or plastic surfaces from a dilution series; viability determined through RT-PCR from cultures immediately after drying, 0 days post inoculation (dpi) with Vero E6 cells compared with after culture (7 dpi). Means and standard deviations of Ct values are shown.

Inoculum (PFU)	Steel surface		Plastic surface	
	After drying (Ct)	After culture (Ct)	After drying (Ct)	After culture (Ct)
41.25	26.23 ± 0.30	12.65 ± 0.51 Pos	25.95 ± 0.06	11.16 ± 0.19 Pos
4.125	29.27 ± 0.04	12.86 ± 0.01 Pos	29.51 ± 0.29	12.58 ± 1.47 Pos
0.4125	32.54 ± 0.06	36.48 ± 1.80 Neg	32.67 ± 0.07	37.39 ± 0.21 Neg
0.04125	39.22 ± 5.13	41.33 ± 3.45 Neg	36.55 ± 0.23	39.76 ± 4.61 Neg

FIGURE LEGENDS

Figure 1. Proportion of environmental samples suspected or positive by item sampled. The number of the x axis represented the number of each item sampled.

Figure 2. SARS-CoV-19 E gene copy number from surface swabs. The quantity of E gene copy number per swab is shown. Suspect samples = blue dots; positive samples = red dots; negative samples = black dots.

Supplemental Figure 1: Trends in daily number of inpatients with COVID-19; the grey box indicates when surface and air samples were collected

Figure 1.





Figure 2.



Supplemental Figure 1:

